Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex J Poot

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Oncotarget|April 19, 2017
Development of [11C]vemurafenib employing a carbon-11 carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma tumor xenograftsPaul Slobbe, Albert D Windhorst, Kevin Adamzek, et al.
Proteomics|December 14, 2006
Selective enrichment of Ser-/Thr-phosphorylated peptides in the presence of Ser-/Thr-glycosylated peptidesAlex J Poot, Eelco Ruijter, Timo Nuijens, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 12, 2024
[<sup>68</sup>Ga]Ga-RAYZ-8009: A Glypican-3-Targeted Diagnostic Radiopharmaceutical for Hepatocellular Carcinoma Molecular Imaging-A First-in-Human Case SeriesAlex J Poot, Constantin Lapa, Wolfgang A Weber, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 5, 2022
Hyperpolarized [5-<sup>13</sup>C,4,4-<sup>2</sup>H<sub>2</sub>,5-<sup>15</sup>N]-L-glutamine provides a means of annotating in vivo metabolic utilization of glutamineRoozbeh Eskandari, Nathaniel Kim, Arsen Mamakhanyan, et al.
The British Journal of Radiology|July 7, 2026
Radioligand therapy for paediatric patients with solid tumoursLeonor Teles, Nelleke Tolboom, Alex J Poot, et al.
Chemmedchem|November 10, 2012
Directed modulation of protein kinase C isozyme selectivity with bisubstrate-based inhibitorsLoek T M van Wandelen, Jeroen van Ameijde, Ahmed S A Mady, et al.
Lung Cancer (Amsterdam, Netherlands)|April 9, 2021
Identifying advanced stage NSCLC patients who benefit from afatinib therapy using <sup>18</sup>F-afatinib PET/CT imagingEveline A van de Stadt, Maqsood Yaqub, Adriaan A Lammertsma, et al.
Scientific Reports|September 7, 2016
Sampling Hyperpolarized Molecules Utilizing a 1 Tesla Permanent Magnetic FieldSui Seng Tee, Valentina DiGialleonardo, Roozbeh Eskandari, et al.
Molecular Pharmaceutics|October 19, 2018
Synthesis and Preclinical Evaluation of the First Carbon-11 Labeled PET Tracers Targeting Substance P<sub>1-7</sub>Aleksandra Pekošak, Janez Ž Bulc, Špela Korat, et al.
EJNMMI Research|April 9, 2015
A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing micePaul Slobbe, Albert D Windhorst, Marijke Stigter-van Walsum, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Oncotarget|April 19, 2017
Development of [11C]vemurafenib employing a carbon-11 carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma tumor xenograftsPaul Slobbe, Albert D Windhorst, Kevin Adamzek, et al.
Proteomics|December 14, 2006
Selective enrichment of Ser-/Thr-phosphorylated peptides in the presence of Ser-/Thr-glycosylated peptidesAlex J Poot, Eelco Ruijter, Timo Nuijens, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 12, 2024
[<sup>68</sup>Ga]Ga-RAYZ-8009: A Glypican-3-Targeted Diagnostic Radiopharmaceutical for Hepatocellular Carcinoma Molecular Imaging-A First-in-Human Case SeriesAlex J Poot, Constantin Lapa, Wolfgang A Weber, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 5, 2022
Hyperpolarized [5-<sup>13</sup>C,4,4-<sup>2</sup>H<sub>2</sub>,5-<sup>15</sup>N]-L-glutamine provides a means of annotating in vivo metabolic utilization of glutamineRoozbeh Eskandari, Nathaniel Kim, Arsen Mamakhanyan, et al.
The British Journal of Radiology|July 7, 2026
Radioligand therapy for paediatric patients with solid tumoursLeonor Teles, Nelleke Tolboom, Alex J Poot, et al.
Chemmedchem|November 10, 2012
Directed modulation of protein kinase C isozyme selectivity with bisubstrate-based inhibitorsLoek T M van Wandelen, Jeroen van Ameijde, Ahmed S A Mady, et al.
Lung Cancer (Amsterdam, Netherlands)|April 9, 2021
Identifying advanced stage NSCLC patients who benefit from afatinib therapy using <sup>18</sup>F-afatinib PET/CT imagingEveline A van de Stadt, Maqsood Yaqub, Adriaan A Lammertsma, et al.
Scientific Reports|September 7, 2016
Sampling Hyperpolarized Molecules Utilizing a 1 Tesla Permanent Magnetic FieldSui Seng Tee, Valentina DiGialleonardo, Roozbeh Eskandari, et al.
Molecular Pharmaceutics|October 19, 2018
Synthesis and Preclinical Evaluation of the First Carbon-11 Labeled PET Tracers Targeting Substance P<sub>1-7</sub>Aleksandra Pekošak, Janez Ž Bulc, Špela Korat, et al.
EJNMMI Research|April 9, 2015
A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing micePaul Slobbe, Albert D Windhorst, Marijke Stigter-van Walsum, et al.
Pageof 6